Discover how BridgeBio’s encaleret aims to transform treatment for
BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)
Discover how BridgeBio’s encaleret aims to transform treatment for